Dr. Sebastian Beyer, LL.M. (Auckland)

Sebastian is a specialist in company law and capital market law. His clients primarily include listed companies and capital market-oriented corporations, investment banks, and other capital market participants.

The focus of his consulting practice is on capital market transactions, in particular, on share placings, admissions to listings on the stock market, as well as on official takeovers. Sebastian also advises executive boards and supervisory boards of listed companies on all legal and strategic matters.

显示完整简历隐藏完整简历

职业发展

Since 2016	Salary Partner, Taylor Wessing
Since 2011	Associate, Taylor Wessing
2009 – 2011	Legal internship, Düsseldorf and Hong Kong

教育

2008 – 2009	Doctoral degree, dissertation on the independence of supervisory board members under special consideration of US American law, University of Trier
2007	LL.M. with a focus on corporate law, University of Auckland (New Zealand)
2007	First state examination

2002 – 2007

Degree in legal studies, University of Trier

更多更少

Publications

#stayonboard – Das neue Recht auf Mandatspause, in: Der Betrieb, 09/2021

Aus AG wird N.V. – Der grenzüberschreitende Formwechsel einer deutschen AG in die Niederlande, in: AHA24x7, 09/2021

Nach der Krise ist vor der Krise - was müssen Vorstand und Aufsichtsrat eines Bundesligisten bei Transferentscheidungen beachten?, Audit Committee Quarterly, p. 28, 2020

Neue Grenzen bei der gerichtlichen Bestellung von Aufsichtsratsmitgliedern, in: NZG, 2014, p. 61

Aggressive Aktionäre als Reputationsrisiko, in: Börsen-Zeitung, 09/2014, p. 9, with Dr. Lars-Gerrit Lüßmann

Die Unabhängigkeit des Aufsichtsratsmitglieds unter besonderer Berücksichtigung des US-amerikanischen Rechts, Verlag Dr. Kovac, 2009

语言

English

French

专长

执业领域和服务团队公司/并购与资本市场风险投资环境、社会和公司治理 (ESG)股权资本市场一般企业

行业酒店与休闲金融机构和保险汽车技术与出行房地产

Experience

Formycon	Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.
Hauck & Aufhäuser	A Taylor Wessing team led by Frankfurt-based partners Lars-Gerrit Lüßmann and Ulrich Reers advised Hauck & Aufhäuser Investment Banking and Polish universal bank mBank in their role as exchange trustee and settlement agent on the voluntary public takeover/exchange offer by Frankfurt-listed Vita 34 AG, Leipzig, to the shareholders of Warsaw-listed stem cell bank Polski Bank Komórek Macierzystych S.A, Warsaw (PBKM). The transaction is the first cross-border exchange offer for a Polish listed company to date.
Eckert & Ziegler Strahlen- und Medizintechnik AG on its public takeover of the Belgian company Eckert & Ziegler BEBIG SA	Eckert & Ziegler Strahlen- und Medizintechnik AG, a German FSE stock listed company on all aspects of a cross-border merger. Eckert & Ziegler Strahlen- und Medizintechnik AG, one of the world's largest suppliers of isotope technology components for radiation therapy and nuclear medicine with headquarters in Berlin, as absorbing entity merged with the Belgian Eckert & Ziegler BEBIG SA, which was listed on the Euronext Brussels stock exchange. The transaction is a rare example of cross-border mergers of two listed companies on the basis of the European harmonized requirements of the EU Company Directive (EU) 2017/1132.